ProtoKinetix, Inc., a biotechnology company focused on the research and development of anti-aging glycoproteins known as AAGPs®, reported a net loss of $393,650 for the fiscal year ending December 31, 2025, compared to a loss of $364,188 in the previous year. The company has not generated any revenue during this period, maintaining a consistent trend of no operational income. Total operating expenses increased to $393,650 from $364,188, primarily driven by higher professional fees, which rose to $177,610 from $144,806, largely due to legal work related to shareholder voting and patent portfolio valuation.
In terms of research and development, ProtoKinetix incurred expenses of $106,613, up from $99,625 in 2024, attributed to increased storage fees for its molecule inventory. The company is shifting its focus towards leveraging positive study findings and is actively seeking industry partnerships to advance the development of AAGP®. General and administrative expenses decreased slightly to $58,135 from $61,470, reflecting cost-cutting measures in marketing and public relations.
The company’s cash position remains precarious, with only $1,118 in cash and a negative working capital of $183,266 as of December 31, 2025. This financial strain raises concerns about its ability to continue operations without securing additional funding. The company has indicated that it will need to raise capital to support ongoing research and development efforts, as well as to meet its operational obligations. The lack of revenue generation and reliance on external funding sources pose significant risks to its business continuity.
ProtoKinetix has also made strides in its research initiatives, including the submission of a research paper on cell characterization for the treatment of Type-1 Diabetes, which reflects its commitment to advancing its scientific endeavors. However, the company faces challenges in achieving market acceptance for its potential products, as competition in the biotechnology sector is intense and rapidly evolving. The management has acknowledged the need for strategic partnerships and increased funding to navigate these challenges effectively.
Looking ahead, ProtoKinetix's future remains uncertain, heavily dependent on its ability to secure financing and successfully develop its AAGP® product line. The company has expressed intentions to enhance its research capabilities and explore collaborations, but the ongoing financial losses and lack of operational revenue underscore the critical need for a robust funding strategy to sustain its business model and achieve its long-term objectives.
About ProtoKinetix, Inc.
ProtoKinetix, Inc. is a biotech research company developing anti-aging glycoproteins (AAGPs) for medical applications. Focused on scientific validation and commercialization, it explores therapies for cell preservation and regenerative medicine. Operating primarily through collaborations, it holds intellectual property, seeks regulatory approval, and aims to bring innovative health solutions to large markets. The company relies on funding, partnerships, and intellectual property protection.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov